Form 4: Immunome Inc. Insider Sells Shares Under 10b5-1 Plan

Immunome Inc. Chief Business Officer Kinney Horn sold 1,092 shares of common stock for $25 per share, totaling $27,300, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Kinney Horn, Chief Business Officer of Immunome Inc., sold 1,092 shares of common stock on July 7, 2026.
• The sale was executed at a price of $25.00 per share, resulting in a total transaction value of $27,300.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2026.
• Following the sale, the reporting person beneficially owns 0 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves an insider selling shares, the transaction was conducted under a pre-established Rule 10b5-1 plan, mitigating concerns about opportunistic trading.

Negatives

• Insider selling can sometimes be interpreted as a negative signal by the market, suggesting a lack of confidence in future stock performance, although this sale was conducted under a pre-planned trading strategy.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance or strategic direction.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan indicates a structured approach to stock sales, often employed by executives to diversify holdings or manage personal finances without appearing to trade on material non-public information.

Stakeholder Impact

• Shareholders: The sale by an executive may be observed, but the use of a 10b5-1 plan suggests it's a pre-determined transaction, potentially reducing negative sentiment compared to an unannounced sale.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Immunome Inc., IMNM, Beneficial Ownership, Securities Exchange Act